• Muhammad Nasir Jamil Department of Urology, Ayub Medical College, Abbottabad
  • Sadia Irum Department of Gynae/Obs, Ayub Medical College Abbottabad
  • Ehsan ul Islam Department of Urolog, yAyub Medical College Abbottabad


Overactive Bladder, Mirabegron, Urgency, Solifenacin


Background: Overactive bladder is mostly treated with a combination of behavioural interventions and commonly prescribed anti-muscarinic medication therapy, including solifenacin, which has considerable side effects and lowers the quality of life. Mirabegron relaxes the detrusor muscle and is a recently approved drug for the treatment of OAB. This study examined the effectiveness and safety of two medications, solifenacin and mirabegron. Methods: This study was a comparative cross-sectional study conducted at Sami Medical Center, Abbottabad for a period of 6 months from August 2022 to January 2023. Female patients of aged ≥18 years with symptoms of OAB were enrolled. Results: Current study showed that the average age of patients was 37.47±12.48 years in Group S and 39.93±7.93 in Group M. The population consists of 60 (100%) females. After 4 weeks of follow up dizziness, dry mouth, constipation hypertension and blurred vision were found insignificant between both groups with p-values of 0.312, 0.161, 0.076, 0.076, and 0.313 respectively. OABSS score improved significantly and after therapy 4.20±1.32 in Group S and 3.43±1.13 in Group M. There was no significant difference in frequency of treatment withdrawal p-value 0.150. Conclusion: When it comes to relieving symptoms of OAB, both solifenacin and mirabegron are effective. The OABSS improved with both drugs; however, mirabegron was associated with fewer treatment-related adverse events. We advocate using mirabegron as the first-line treatment. Solifenacin can be utilized if patients are no longer getting the desired effects from Mirabegron.

Author Biographies

Muhammad Nasir Jamil, Department of Urology, Ayub Medical College, Abbottabad

Department of Urology, Ayub Medical College, Abbottabad

Sadia Irum, Department of Gynae/Obs, Ayub Medical College Abbottabad


Ehsan ul Islam, Department of Urolog, yAyub Medical College Abbottabad



Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol 2017;11(3):117–25.

Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3(1):46–53.

Shawahna R, Hijaz H, Jallad K, Abushamma M, Sawafta M. Prevalence of overactive bladder symptoms and their impact on health-related quality of life of medical and dentistry students: a multicenter cross-sectional study. BMC Urol 2021;21(1):142.

Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on health‐related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011;59(8):1465–70.

Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study. BJU Int 2008;101(11):1388–95.

Najafi Z, Morowatisharifabad MA, Jambarsang S, Rezaeipandari H, Hemayati R. Urinary incontinence and related quality of life among elderly women in Tabas, South Khorasan, Iran. BMC Urol 2022;22(1):214.

Igawa Y, Aizawa N, Michel MC. β3‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions? Br J Pharmacol 2019;176(14):2525–38.

Takeda H, Matsuzawa A, Igawa Y, Yamazaki Y, Kaidoh K, Akahane S, et al. Functional characterization of β-adrenoceptor subtypes in the canine and rat lower urinary tract. J Urol 2003;170(2):654–8.

O’Kane M, Robinson D, Cardozo L, Wagg A, Abrams P. Mirabegron in the Management of Overactive Bladder Syndrome. Int J Womens Health 2022;14:1337–50.

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65(4):755–65.

Schiavi MC, Faiano P, D'Oria O, Zullo MA, Muzii L, Benedetti Panici P. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis. J Obstet Gynaecol Res 2018;44(3):524–31.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms 2021;13(4):425–34.

Acar Ö, Erton ML, Tarcan T. Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make? J Urol Surg 2019;6(2):85.

Kobayashi M, Nukui A, Kamai T. Comparative efficacy and tolerability of antimuscarinic agents and the selective β3‐adrenoceptor agonist, mirabegron, for the treatment of overactive bladder: which is more preferable as an initial treatment? Low Urin Tract Symptoms 2018;10(2):158–66.

Amend GM, Baird A, Baradaran N, Bele U, Breyer BN, Cito G, et al. Influences and Complications. In: Drake M, Cocci A, Pereira e Silva R, editors. Lower Urinary Tract Symptoms in Adults [Internet]. Cham: Springer International Publishing; 2020 [cited 2023 Feb]. p.217–66. Available from:

Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 2018;8(11):e021889.

Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110(11):1767–74.

Additional Files